Nexentis files prospectus for $2.9 million offering
Nexentis Technologies Inc. filed an SEC prospectus to offer 410,998 common shares and warrants at $7.056 per unit, targeting $2.9 million in gross proceeds. This capital raise supports its subsidiary MitoCareX Bio Ltd., which recently partnered with Boltz, PBC to use AI for discovering small-molecule therapies for cancer and metabolic diseases.
*this image is generated using AI for illustrative purposes only.
Nexentis Technologies Inc. (NASDAQ: NXTS) filed a prospectus with the SEC to sell 410,998 common shares and an equal number of five-year warrants to raise approximately $2.9 million. Both the shares and warrants are priced at $7.056 per unit. The filing follows the company's recent announcement of a strategic partnership focused on artificial intelligence drug discovery.
The offering details were disclosed in a Form 424B5 prospectus filed with the Securities and Exchange Commission. Nexentis intends to use the capital raised to further its business initiatives, which include the operations of its wholly owned subsidiary, MitoCareX Bio Ltd., and investments in European solar energy projects.
Strategic Partnership
The capital raise coincides with MitoCareX Bio's engagement with Boltz, PBC, an AI research lab. This partnership aims to accelerate the identification of novel small-molecule scaffolds targeting selected solute carrier (SLC) proteins. The initiative combines MitoCareX’s proprietary MITOLINE® algorithm platform with Boltz’s foundation models for predicting biomolecular structure and binding affinity.
Technology and Objectives
The collaboration focuses on strengthening target-specific virtual screening campaigns for challenging transporter proteins. The goal is to improve hit identification for cancers and metabolic diseases. MitoCareX will retain full control over its discovery programs and any candidates advanced using this approach. Boltz’s platform provides a hosted environment combining biomolecular foundation models, managed compute, and scientist-oriented workflows.
| Aspect | Detail |
|---|---|
| Subsidiary | MitoCareX Bio Ltd. |
| Partner | Boltz, PBC |
| Technology | MITOLINE® algorithm + Boltz AI |
| Focus | SLC transport proteins |
| Objective | Small-molecule discovery |
| Target Areas | Cancers, metabolic diseases |
Market Performance
Nexentis has a market capitalization of $13.55 million and is down 77.75% over the past 12 months. The stock recently saw significant volatility, surging on the AI drug news before declining after the offering announcement. The company currently trades at about 47.6% of its 52-week range, with a high of $23.80 and a low of $3.38.
What specific milestones or timelines has Nexentis set for the AI drug discovery partnership with Boltz?
How will the company balance capital allocation between its biotech subsidiary and European solar energy projects?
What is the expected dilutive impact of the new share issuance on existing shareholders?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
